CureVac NV
http://www.curevac.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CureVac NV
GSK Stays In mRNA Flu Vaccine Race With Phase II Win
Its vaccine candidate will now proceed to Phase III, but might be hard pressed to compete against Moderna’s flu plus COVID-19 combination shot.
Stock Watch: Biotechs Sell The Family Silver
When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.
GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma
Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- CureVac GmbH
- CureVac BV
- Frame Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice